Please assess the completion status of the following clinical trial:

Trial Title: 18F-AV-1451 Autopsy Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Have a projected life expectancy of ≤ 6 months~* Can tolerate a 20 minute PET scan~* Give informed consent or have a legally authorized representative to consent for study procedures and brain donation consistent with the legal requirements of the State in which they die~Exclusion Criteria:~* Aggressively being treated with life sustaining measures~* Known to have a structural brain lesion that would interfere either with PET imaging or pathological assessment~* Clinically significant infectious disease~* Currently receiving any investigational medications except with permission from the study sponsor~* Participated in an experimental study with an amyloid or tau targeting agent~* Suspected encephalopathy due to alcoholism or end-stage liver disease~* Females of childbearing potential~* History of risk factors for Torsades de Pointes or are currently taking medication known to cause QT prolongation

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Flortaucipir PET Scan (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).